TABLE 4.
Post hoc Bayesian estimates of pharmacokinetic parameters and derived secondary parameters for piperaquine in pregnant and nonpregnant women
| Parametera | Median (IQR) value |
P value | |
|---|---|---|---|
| Nonpregnant (n = 33) | Pregnant (n = 32) | ||
| MTT (h) | 0.942 (0.813–1.17) | 0.977 (0.766–1.75) | 0.33 |
| NN | 2.57 (1.58–5.50) | 1.76 (1.11–5.44) | 0.28 |
| CL/FPQ (liters/h) | 53.8 (49.7–58.2) | 73.5 (69.4–78.4) | <0.001 |
| VC/FPQ (liters) | 2,601 (2,321–3,208) | 2,296 (2,117–2,720) | 0.054 |
| Q1/FPQ (liters/h) | 81.1 (73.6–84.4) | 77.7 (75.1–83.6) | 0.49 |
| VP1/FPQ (liters) | 18,639 (16,395–19,674) | 17,604 (16,827–19,415) | 0.49 |
| Q2/FPQ (liters/h) | 451 (410–470) | 432 (418–465) | 0.49 |
| VP2/FPQ (liters) | 7,623 (6,706–8,047) | 7,200 (6,882–7,941) | 0.49 |
| t½α (h) | 2.61 (2.33–2.85) | 2.33 (2.21–2.51) | 0.019 |
| t½β (h) | 50.7 (49.2–52.0) | 45.8 (45–46.8) | <0.001 |
| t½γ (h) | 488 (478–499) | 382 (374–388) | <0.001 |
| AUC0–∞ (μg · h/liter) | 35,644 (29,546–39,541) | 23,721 (21,481–27,951) | <0.001 |
a
Abbreviations: MTT, mean transit time; NN, number of transit compartments; CL/FPQ, clearance; VC/FPQ, central volume of distribution; Q1/FPQ, intercompartmental clearance for VP1/FPQ; VP1/FPQ, first peripheral volume of distribution; Q2/FPQ, intercompartmental clearance for VP2/FPQ; VP2/FPQ, second peripheral volume of distribution; t½α, t½β, and t½γ (first and second distribution and elimination half-lives, respectively; Cmax, maximum plasma concentration; AUC0–∞, area under the plasma drug concentration-time curve.